Australian Biotech CSL Sees Talecris Acquisition As Ticket To Grow Plasma Therapeutics
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - In what is being called the biggest Australian biotech acquisition, Melbourne-based CSL Limited inked a deal to acquire Talecris Biotherapeutics for $3.1 billion, CSL announced Aug. 13
You may also be interested in...
U.S. FTC Blocks Australian CSL’s Acquisition of Talecris, Noting Consolidation Would Reduce Competition
PERTH, Australia - The U.S. Federal Trade Commission has authorized a lawsuit to stop Australian-based CSL Limited's $3.1 billion acquisition of Talecris Biotherapeutics, charging that the deal "would be illegal and would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies," the commission announced May 27
U.S. FTC Blocks Australian CSL’s Acquisition of Talecris, Noting Consolidation Would Reduce Competition
PERTH, Australia - The U.S. Federal Trade Commission has authorized a lawsuit to stop Australian-based CSL Limited's $3.1 billion acquisition of Talecris Biotherapeutics, charging that the deal "would be illegal and would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies," the commission announced May 27
New Zealand’s PHARMAC Funds J&J’s Concerta, Topamax: Australia/New Zealand Regulatory Roundup
PERTH, Australia - New Zealand's Pharmaceutical Management Agency will now fund Johnson & Johnson's Concerta (methylphenidate extended release) for the treatment of attention deficit hyperactivity disorder, beginning Sept. 1